This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 101/11/1164    most recent CIRCRESAHA.107.160614v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hirotani, S. Articles by Sadoshima, J. Search for Related Content PubMed PubMed Citation Articles by Hirotani, S. Articles by Sadoshima, J. Related Collections Cardio-renal physiology/pathophysiology Animal models of human disease Cell signalling/signal transduction Hypertrophy Related Article

(Circulation Research. 2007;101:1164.)
© 2007 American Heart Association, Inc.

Integrative Physiology

Inhibition of Glycogen Synthase Kinase 3ß During Heart Failure Is Protective

Shinichi Hirotani^*, Peiyong Zhai^*, Hideharu Tomita, Jonathan Galeotti, Juan Pablo Marquez, Shumin Gao, Chull Hong, Atsuko Yatani, Jesús Avila, Junichi Sadoshima

From the Cardiovascular Research Institute (S.H., P.Z., H.T., J.G., J.P.M., S.G., C.H., A.Y., J.S.), Department of Cell Biology and Molecular Medicine, University of Medicine & Dentistry of New Jersey, New Jersey Medical School, Newark; and Centro de Biología Molecular "Severo Ochoa" (J.A.), Facultad de Ciencias, Campus de Cantoblanco, Universidad Autónoma de Madrid, Spain.

Correspondence to Junichi Sadoshima, MD, PhD, Cardiovascular Research Institute, UMDNJ, 185 South Orange Ave, MSB G-609, Newark, NJ 07103. E-mail Sadoshju{at}umdnj.edu

Glycogen synthase kinase (GSK)-3, a negative regulator of cardiac hypertrophy, is inactivated in failing hearts. To examine the histopathological and functional consequence of the persistent inhibition of GSK-3ß in the heart in vivo, we generated transgenic mice with cardiac-specific overexpression of dominant negative GSK-3ß (Tg-GSK-3ß-DN) and tetracycline-regulatable wild-type GSK-3ß. GSK-3ß-DN significantly reduced the kinase activity of endogenous GSK-3ß, inhibited phosphorylation of eukaryotic translation initiation factor 2B, and induced accumulation of ß-catenin and myeloid cell leukemia-1, confirming that GSK-3ß-DN acts as a dominant negative in vivo. Tg-GSK-3ß-DN exhibited concentric hypertrophy at baseline, accompanied by upregulation of the -myosin heavy chain gene and increases in cardiac function, as evidenced by a significantly greater E_max after dobutamine infusion and percentage of contraction in isolated cardiac myocytes, indicating that inhibition of GSK-3ß induces well-compensated hypertrophy. Although transverse aortic constriction induced a similar increase in hypertrophy in both Tg-GSK-3ß-DN and nontransgenic mice, Tg-GSK-3ß-DN exhibited better left ventricular function and less fibrosis and apoptosis than nontransgenic mice. Induction of the GSK-3ß transgene in tetracycline-regulatable wild-type GSK-3ß mice induced left ventricular dysfunction and premature death, accompanied by increases in apoptosis and fibrosis. Overexpression of GSK-3ß-DN in cardiac myocytes inhibited tumor necrosis factor-–induced apoptosis, and the antiapoptotic effect of GSK-3ß-DN was abrogated in the absence of myeloid cell leukemia-1. These results suggest that persistent inhibition of GSK-3ß induces compensatory hypertrophy, inhibits apoptosis and fibrosis, and increases cardiac contractility and that the antiapoptotic effect of GSK-3ß inhibition is mediated by myeloid cell leukemia-1. Thus, downregulation of GSK-3ß during heart failure could be compensatory.

Key Words: GSK-3ß • heart failure • cardiac hypertrophy • apoptosis

Related Article:

Not All Hypertrophy Is Created Equal

Ronglih Liao and Thomas Force
Circ. Res. 2007 101: 1069-1072. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				M. Juhaszova, D. B. Zorov, Y. Yaniv, H. B. Nuss, S. Wang, and S. J. Sollott Role of Glycogen Synthase Kinase-3{beta} in Cardioprotection Circ. Res., June 5, 2009; 104(11): 1240 - 1252. [Abstract] [Full Text] [PDF]

				Y. Wang, W. Feng, W. Xue, Y. Tan, D. W. Hein, X.-K. Li, and L. Cai Inactivation of GSK-3{beta} by Metallothionein Prevents Diabetes-Related Changes in Cardiac Energy Metabolism, Inflammation, Nitrosative Damage, and Remodeling Diabetes, June 1, 2009; 58(6): 1391 - 1402. [Abstract] [Full Text] [PDF]

				A. Das, F. N. Salloum, L. Xi, Y. J. Rao, and R. C. Kukreja ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1236 - H1243. [Abstract] [Full Text] [PDF]

				S. Miyamoto, M. Rubio, and M. A. Sussman Nuclear and mitochondrial signalling Akts in cardiomyocytes Cardiovasc Res, May 1, 2009; 82(2): 272 - 285. [Abstract] [Full Text] [PDF]

				T. Matsuda, P. Zhai, Y. Maejima, C. Hong, S. Gao, B. Tian, K. Goto, H. Takagi, M. Tamamori-Adachi, S. Kitajima, et al. Distinct roles of GSK-3{alpha} and GSK-3{beta} phosphorylation in the heart under pressure overload PNAS, December 30, 2008; 105(52): 20900 - 20905. [Abstract] [Full Text] [PDF]

				A. J.G. Horrevoets Kallikrein teams up with GSK-3{beta} in heart failure prevention Cardiovasc Res, December 1, 2008; 80(3): 328 - 329. [Full Text] [PDF]

				A. Das, L. Xi, and R. C. Kukreja Protein Kinase G-dependent Cardioprotective Mechanism of Phosphodiesterase-5 Inhibition Involves Phosphorylation of ERK and GSK3{beta} J. Biol. Chem., October 24, 2008; 283(43): 29572 - 29585. [Abstract] [Full Text] [PDF]

				S. Das, R. Wong, N. Rajapakse, E. Murphy, and C. Steenbergen Glycogen Synthase Kinase 3 Inhibition Slows Mitochondrial Adenine Nucleotide Transport and Regulates Voltage-Dependent Anion Channel Phosphorylation Circ. Res., October 24, 2008; 103(9): 983 - 991. [Abstract] [Full Text] [PDF]

				R. Liao and T. Force Not All Hypertrophy Is Created Equal Circ. Res., November 26, 2007; 101(11): 1069 - 1072. [Full Text] [PDF]